These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7990 related articles for article (PubMed ID: 24817989)

  • 1. Genetic alterations in quadruple malignancies of a patient with multiple sclerosis: their role in malignancy development and response to therapy.
    Milosevic Z; Tanic N; Bankovic J; Stankovic T; Buta M; Lavrnic D; Milovanovic Z; Pupic G; Stojkovic S; Milinkovic V; Ito Y; Dzodic R
    Int J Clin Exp Pathol; 2014; 7(4):1826-33. PubMed ID: 24817989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
    Komminoth P
    Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
    Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
    Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
    Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS proto-oncogene in medullary thyroid carcinoma.
    Moura MM; Cavaco BM; Leite V
    Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.
    Moses W; Weng J; Khanafshar E; Duh QY; Clark OH; Kebebew E
    J Surg Res; 2010 May; 160(2):179-83. PubMed ID: 19765726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
    Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
    Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
    Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
    Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
    Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.
    Wei S; LiVolsi VA; Montone KT; Morrissette JJ; Baloch ZW
    Endocr Pathol; 2016 Dec; 27(4):359-362. PubMed ID: 27379493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
    Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism.
    Rotondi M; Ercolino T; Fonte R; Lagonigro MS; Leporati P; Villani L; La Manna L; Mannelli M; Chiovato L
    J Endocrinol Invest; 2009 Feb; 32(2):115-8. PubMed ID: 19411807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
    Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
    Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
    Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
    J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
    Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
    Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 400.